Apolipoprotein A-V is a potential target for treating coronary artery disease: evidence from genetic and metabolomic analyses.

Ibi, DorinaBoot, ManonDollé, Martijn E TJukema, J WouterRosendaal, Frits RChristodoulides, ConstantinosNeville, Matt JKoivula, RobertRensen, Patrick C NKarpe, FredrikNoordam, RaymondWillems van Dijk, Ko2022-03-212022-03-212022-03-093527841010.1016/j.jlr.2022.100193http://hdl.handle.net/10029/625633enCopyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.Cardiovascular diseaseLDLclinical datafactorial analysisgenetic variationhyperlipidemialipid-lowering therapylipoprotein lipase (LPL)lipoproteinstriglyceridesApolipoprotein A-V is a potential target for treating coronary artery disease: evidence from genetic and metabolomic analyses.Article1539-7262Journal of lipid research 2022;100193